1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Oncolytic Virus-Based Gene Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Oncolytic Virus-Based Gene Therapy Market, by Virus Type
8.1.1. Herpes Simplex Virus (HSV)
8.1.1.1. Market Revenue and Forecast
8.1.2. Adenovirus
8.1.2.1. Market Revenue and Forecast
8.1.3. Vaccinia Virus
8.1.3.1. Market Revenue and Forecast
8.1.4. Newcastle Disease Virus (NDV)
8.1.4.1. Market Revenue and Forecast
8.1.5. Reovirus
8.1.5.1. Market Revenue and Forecast
8.1.6. Measles Virus
8.1.6.1. Market Revenue and Forecast
9.1. Oncolytic Virus-Based Gene Therapy Market, by Delivery Route
9.1.1. Intratumoral
9.1.1.1. Market Revenue and Forecast
9.1.2. Intravenous
9.1.2.1. Market Revenue and Forecast
9.1.3. Intraperitoneal
9.1.3.1. Market Revenue and Forecast
9.1.4. Intrathecal
9.1.4.1. Market Revenue and Forecast
9.1.5. Subcutaneous
9.1.5.1. Market Revenue and Forecast
10.1. Oncolytic Virus-Based Gene Therapy Market, by Cancer Type
10.1.1. Melanoma
10.1.1.1. Market Revenue and Forecast
10.1.2. Glioblastoma
10.1.2.1. Market Revenue and Forecast
10.1.3. Head and Neck Cancer
10.1.3.1. Market Revenue and Forecast
10.1.4. Head and Neck Cancer
10.1.4.1. Market Revenue and Forecast
10.1.5. Lung Cancer
10.1.5.1. Market Revenue and Forecast
10.1.6. Prostate Cancer
10.1.6.1. Market Revenue and Forecast
10.1.7. Pancreatic Cancer
10.1.7.1. Market Revenue and Forecast
10.1.8. Liver Cancer
10.1.8.1. Market Revenue and Forecast
11.1. Oncolytic Virus-Based Gene Therapy Market, by End-User
11.1.1. Pharmaceutical & Biotechnology Companies
11.1.1.1. Market Revenue and Forecast
11.1.2. Contract Development and Manufacturing Organizations (CDMOs)
11.1.2.1. Market Revenue and Forecast
11.1.3. Academic & Research Institutes
11.1.3.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Virus Type
12.1.2. Market Revenue and Forecast, by Delivery Route
12.1.3. Market Revenue and Forecast, by Cancer Type
12.1.4. Market Revenue and Forecast, by End-User
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Virus Type
12.1.5.2. Market Revenue and Forecast, by Delivery Route
12.1.5.3. Market Revenue and Forecast, by Cancer Type
12.1.5.4. Market Revenue and Forecast, by End-User
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Virus Type
12.1.6.2. Market Revenue and Forecast, by Delivery Route
12.1.6.3. Market Revenue and Forecast, by Cancer Type
12.1.6.4. Market Revenue and Forecast, by End-User
12.2. Europe
12.2.1. Market Revenue and Forecast, by Virus Type
12.2.2. Market Revenue and Forecast, by Delivery Route
12.2.3. Market Revenue and Forecast, by Cancer Type
12.2.4. Market Revenue and Forecast, by End-User
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Virus Type
12.2.5.2. Market Revenue and Forecast, by Delivery Route
12.2.5.3. Market Revenue and Forecast, by Cancer Type
12.2.5.4. Market Revenue and Forecast, by End-User
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Virus Type
12.2.6.2. Market Revenue and Forecast, by Delivery Route
12.2.6.3. Market Revenue and Forecast, by Cancer Type
12.2.6.4. Market Revenue and Forecast, by End-User
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Virus Type
12.2.7.2. Market Revenue and Forecast, by Delivery Route
12.2.7.3. Market Revenue and Forecast, by Cancer Type
12.2.7.4. Market Revenue and Forecast, by End-User
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Virus Type
12.2.8.2. Market Revenue and Forecast, by Delivery Route
12.2.8.3. Market Revenue and Forecast, by Cancer Type
12.2.8.4. Market Revenue and Forecast, by End-User
12.3. APAC
12.3.1. Market Revenue and Forecast, by Virus Type
12.3.2. Market Revenue and Forecast, by Delivery Route
12.3.3. Market Revenue and Forecast, by Cancer Type
12.3.4. Market Revenue and Forecast, by End-User
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Virus Type
12.3.5.2. Market Revenue and Forecast, by Delivery Route
12.3.5.3. Market Revenue and Forecast, by Cancer Type
12.3.5.4. Market Revenue and Forecast, by End-User
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Virus Type
12.3.6.2. Market Revenue and Forecast, by Delivery Route
12.3.6.3. Market Revenue and Forecast, by Cancer Type
12.3.6.4. Market Revenue and Forecast, by End-User
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Virus Type
12.3.7.2. Market Revenue and Forecast, by Delivery Route
12.3.7.3. Market Revenue and Forecast, by Cancer Type
12.3.7.4. Market Revenue and Forecast, by End-User
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Virus Type
12.3.8.2. Market Revenue and Forecast, by Delivery Route
12.3.8.3. Market Revenue and Forecast, by Cancer Type
12.3.8.4. Market Revenue and Forecast, by End-User
12.4. MEA
12.4.1. Market Revenue and Forecast, by Virus Type
12.4.2. Market Revenue and Forecast, by Delivery Route
12.4.3. Market Revenue and Forecast, by Cancer Type
12.4.4. Market Revenue and Forecast, by End-User
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Virus Type
12.4.5.2. Market Revenue and Forecast, by Delivery Route
12.4.5.3. Market Revenue and Forecast, by Cancer Type
12.4.5.4. Market Revenue and Forecast, by End-User
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Virus Type
12.4.6.2. Market Revenue and Forecast, by Delivery Route
12.4.6.3. Market Revenue and Forecast, by Cancer Type
12.4.6.4. Market Revenue and Forecast, by End-User
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Virus Type
12.4.7.2. Market Revenue and Forecast, by Delivery Route
12.4.7.3. Market Revenue and Forecast, by Cancer Type
12.4.7.4. Market Revenue and Forecast, by End-User
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Virus Type
12.4.8.2. Market Revenue and Forecast, by Delivery Route
12.4.8.3. Market Revenue and Forecast, by Cancer Type
12.4.8.4. Market Revenue and Forecast, by End-User
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Virus Type
12.5.2. Market Revenue and Forecast, by Delivery Route
12.5.3. Market Revenue and Forecast, by Cancer Type
12.5.4. Market Revenue and Forecast, by End-User
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Virus Type
12.5.5.2. Market Revenue and Forecast, by Delivery Route
12.5.5.3. Market Revenue and Forecast, by Cancer Type
12.5.5.4. Market Revenue and Forecast, by End-User
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Virus Type
12.5.6.2. Market Revenue and Forecast, by Delivery Route
12.5.6.3. Market Revenue and Forecast, by Cancer Type
12.5.6.4. Market Revenue and Forecast, by End-User
13.1. Sorrento Therapeutics, Inc.
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Amgen, Inc.
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Replimune Group, Inc.
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Oncolytics Biotech, Inc.
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. PsiOxus Therapeutics Ltd.
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Transgene SA
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. SillaJen, Inc.
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Genelux Corporation
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Shanghai Sunway Biotech Co. Ltd.
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Takara Bio, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
